A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting
Public ClinicalTrials.gov record NCT03021018. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Randomized, Parallel-Group, Active-Controlled Study to Assess the Efficacy and Safety of Brivaracetam Administered Intravenously as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting
Study identification
- NCT ID
- NCT03021018
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Interventions
- Brivaracetam Drug
- Lorazepam Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 5, 2017
- Primary completion
- Apr 26, 2018
- Completion
- Apr 26, 2018
- Last update posted
- Dec 15, 2020
2017 – 2018
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ep0087 108 | Birmingham | Alabama | 35294 | — |
| Ep0087 117 | Tucson | Arizona | 85724 | — |
| Ep0087 112 | Orlando | Florida | 32806 | — |
| Ep0087 115 | Chicago | Illinois | 60611 | — |
| Ep0087 113 | Chicago | Illinois | 60612 | — |
| Ep0087 119 | Wichita | Kansas | 67214 | — |
| Ep0087 116 | Belmont | Massachusetts | 02478 | — |
| Ep0087 106 | Boston | Massachusetts | 02215 | — |
| Ep0087 107 | Detroit | Michigan | 48201 | — |
| Ep0087 125 | Lebanon | New Hampshire | 03756 | — |
| Ep0087 120 | Rochester | New York | 14642 | — |
| Ep0087 121 | Chapel Hill | North Carolina | 27599 | — |
| Ep0087 105 | Charlotte | North Carolina | 28204 | — |
| Ep0087 123 | Hershey | Pennsylvania | 17033-2360 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03021018, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 15, 2020 · Synced Jun 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03021018 live on ClinicalTrials.gov.